News

First Two Patients Dosed in HemoShear Therapeutics Phase 2 Study

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, dosed the first two patience in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks to advance the first oral therapy designed to directly address underlying biochemical causes of these rare and life-threatening diseases.

HST5040 is being developed by HemoShear to lower toxic metabolites that build up in MMA and PA as a result of genetic deficiencies in key enzymes required to break down certain amino acids from protein. These toxins can result in severe organ damage, developmental deficits, and premature death. Despite the current standard of care involving dietary control, carnitine supplementation, and in more severe cases, organ transplantation, there remains a high unmet medical need in MMA and PA.

As a small molecule, HST5040 has the ability to distribute to all affected tissues and thus has the potential to be active throughout the body, including the liver, kidneys, brain, heart, and muscles. HST5040 is designed for convenient daily administration at home as a liquid formulation taken either orally or through a gastric feeding tube. The FDA has granted HemoShear’s HST5040 Orphan Drug, Fast Track and Rare Pediatric Disease designations to treat MMA and PA.

“There are currently no targeted pharmacologic treatments for MMA or PA that can improve quality of life or extend lifespan for these devastating diseases,” said Kimberly Chapman, MD, PhD, genetic metabolist at Children’s National Hospital in Washington, DC. “The patient community is excited for the possibility of a convenient, daily oral treatment approach.”

The HERO study is enrolling at least 12 patients with MMA or PA aged 2 and older. The study will include three sequential treatment periods: an open-label, within-patient, dose escalation period; followed by a randomized, double-blind, placebo-controlled crossover period; and then an open-label, long-term extension period. If the data are encouraging, enrollment in the long-term extension period of the HERO study may be expanded to include patients who have had liver or kidney transplants and those with additional types of MMA.

The first study participants to receive HST5040 are pediatric PA patients under the care of Jennifer Gannon, MD, the principal investigator at Children’s Mercy Kansas City. Additional study sites include Boston Children’s Hospital, UMPC Children’s Hospital of Pittsburgh, Children’s National Hospital, Rady Children’s Hospital of San Diego, University of Florida, University of Minnesota, University of Utah, Vanderbilt University Medical Center, and Yale Center for Clinical Investigation. More information can be found at www.MMA-PAHero.com or ClinicalTrials.gov (NCT04732429).

“This is a tremendous milestone for patients and families who desperately need a treatment that can potentially target all organs affected by these diseases,” said Jim Powers, Chairman and CEO of HemoShear. “We named this the HERO study because of the challenges brave families face every day living with MMA and PA. We look forward to monitoring the impact of HST5040 on participants in the study.”

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by